277 related articles for article (PubMed ID: 37552439)
21. Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Guarneri V; Passos Coelho JL; Duhoux FP; Egle D; García-Sáenz JÁ; Penault-Llorca F; Selander K; Wildiers H; Zaman K; Laeis P; Lucerna M; Pierga JY
Future Oncol; 2024 Apr; ():. PubMed ID: 38592002
[TBL] [Abstract][Full Text] [Related]
22. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
23. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR; Vilbert M; Rosa VDL; Oliveira JL; Deus MM; Freitas-Junior R
ESMO Open; 2023 Aug; 8(4):101613. PubMed ID: 37481956
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Mishima S; Shitara K
Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
[No Abstract] [Full Text] [Related]
25. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
[No Abstract] [Full Text] [Related]
26. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
28. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone.
Pearson J; Khan A; Bhogal T; Wong H; Law A; Mills S; Santamaria N; Bishop J; Cliff J; Errington D; Hall A; Hart C; Malik Z; Sripadam R; Innes H; Flint H; Langton G; Ahmed E; Jackson R; Palmieri C
ESMO Open; 2023 Dec; 8(6):102033. PubMed ID: 37866031
[TBL] [Abstract][Full Text] [Related]
30. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
[TBL] [Abstract][Full Text] [Related]
32. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
Jørgensen JT
Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer.
Kotani D; Shitara K
Ther Adv Med Oncol; 2021; 13():1758835920986518. PubMed ID: 33473250
[TBL] [Abstract][Full Text] [Related]
34. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Nguyen X; Hooper M; Borlagdan JP; Palumbo A
Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
Nie T; Blair HA
Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
Shi D; Liang X; Li Y; Chen L
PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab Deruxtecan in Patients With
Goto K; Goto Y; Kubo T; Ninomiya K; Kim SW; Planchard D; Ahn MJ; Smit EF; de Langen AJ; Pérol M; Pons-Tostivint E; Novello S; Hayashi H; Shimizu J; Kim DW; Kuo CH; Yang JC; Pereira K; Cheng FC; Taguchi A; Cheng Y; Feng W; Tsuchihashi Z; Jänne PA
J Clin Oncol; 2023 Nov; 41(31):4852-4863. PubMed ID: 37694347
[TBL] [Abstract][Full Text] [Related]
40. A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view.
Liang X; Yan Y; Song G
Transl Breast Cancer Res; 2022; 3():32. PubMed ID: 38751531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
